Blood tests and artificial intelligence are changing how Alzheimer's is assessed. A new tool aims to predict which patients with mild cognitive impairment may go on to develop dementia.
Artificial intelligence is bringing Alzheimer's assessment closer to the stage when doctors need it most: the first signs of cognitive decline. Blood biomarkers are being combined with genetic risk and neuropsychological data to estimate whether mild cognitive impairment may progress to dementia. The approach does more than look for signs of disease in the brain. It tries to forecast how a particular patient may develop.
That distinction matters in Spain. Alzheimer's disease accounts for 60% to 70% of dementia cases there. Alzheimer Europe estimates that 983,920 people were living with dementia in the country in 2025. That was around 2.05% of the population. Across the European Union, the estimate was more than 9 million people in 2025. The figure could exceed 14.3 million by 2050.
A parallel line of research suggests that blood-based p-tau181 may help forecast future cognitive problems as much as six years before they become evident, according to a ScienceAlert report on the underlying study.
ADmit Therapeutics built the technology around MAP-AD®, which carries CE-IVDR marking. It is designed to predict whether mild cognitive impairment will progress to dementia due to Alzheimer's disease. The test combines blood biomarkers based on mitochondrial DNA methylation with ApoE genotype, age and neuropsychological assessment. Next Generation Sequencing and Machine Learning process the information together. Reports published by Libertad Digital and Democrata on 21 September 2026 describe MAP-AD as an in vitro diagnostic product being promoted for use in Europe, rather than only as a laboratory prototype.
The test is aimed at the uncertain period when symptoms have appeared but their course is still unclear.
For patients and clinicians, that forecast adds information that conventional disease markers cannot provide on their own. Marta Barrachina, CEO and co-founder of ADmit Therapeutics and a representative of the AseBio partner company, says amyloid plaques do not explain the full clinical complexity of every patient. Her company's approach puts biological, energy, inflammatory and immune processes alongside genetic and clinical information. It does not treat brain pathology as the only explanation.
Blood-based p-tau217 tests represent a related but distinct development. Cleveland Clinic Consult QD describes Elecsys Phospho-Tau (217P) Plasma as a potential triage tool for the Alzheimer’s diagnostic pathway, while recent dementia research summaries highlight p-tau217 for selecting participants for studies and prevention programs.
This wider model also addresses a long-running problem in Alzheimer's research. Some patients may have beta-amyloid plaques without later developing dementia. That makes it harder to sort participants accurately in clinical trials. Markers linked to cognitive progression could help researchers separate patient groups more precisely. They could also help assess treatments against a clearer clinical trajectory. The emerging p-tau217 research points in the same direction. Biomarker testing is being studied not only to detect Alzheimer's pathology, but also to guide the next diagnostic, research or prevention step.
The subject has also been covered in coverage of Alzheimer's prevalence in Spain. The growing burden of dementia gives these tools a clear public-health rationale. The tests still need to be read as part of a clinical assessment, not used as a standalone prediction of one person's future.
